Conmed Stock Five Year Return
| CNMD Stock | USD 53.50 0.02 0.04% |
Fundamental analysis of CONMED allows traders to better anticipate movements in CONMED's stock price by examining its financial health and performance throughout various phases of its business cycle.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. CONMED Company Five Year Return Analysis
CONMED's Five Year Return is considered one of the best measures to evaluate fund performance, especially from the mid and long term perspective. It shows the total annualized return generated from holding equity for the last five years and represents capital appreciation of the investment, including all dividends, losses, and capital gains distributions.
More About Five Year Return | All Equity Analysis
Five Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Current CONMED Five Year Return | 0.92 % |
Most of CONMED's fundamental indicators, such as Five Year Return, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CONMED is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although Five Year Returns can give a sense of overall investment potential, it is recommended to compare equity performance with similar assets for the same five year time interval. Similarly, comparing overall investment performance over the last five years with the appropriate market index is a great way to determine how this equity instrument will perform during unforeseen market fluctuations.
| Competition |
According to the company disclosure, CONMED has a Five Year Return of 0.92%. This is much higher than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The five year return for all United States stocks is notably lower than that of the firm.
Did you try this?
Run Content Syndication Now
Content SyndicationQuickly integrate customizable finance content to your own investment portal |
| All Next | Launch Module |
CONMED Fundamentals
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0403 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.11 % | ||||
| Current Valuation | 2.47 B | ||||
| Shares Outstanding | 30.95 M | ||||
| Shares Owned By Insiders | 0.50 % | ||||
| Shares Owned By Institutions | 99.50 % | ||||
| Number Of Shares Shorted | 846.97 K | ||||
| Price To Earning | 188.03 X | ||||
| Price To Book | 1.61 X | ||||
| Price To Sales | 1.25 X | ||||
| Revenue | 1.31 B | ||||
| Gross Profit | 743.42 M | ||||
| EBITDA | 272.18 M | ||||
| Net Income | 132.42 M | ||||
| Cash And Equivalents | 33.35 M | ||||
| Cash Per Share | 1.09 X | ||||
| Total Debt | 905.78 M | ||||
| Debt To Equity | 1.45 % | ||||
| Current Ratio | 2.75 X | ||||
| Book Value Per Share | 32.41 X | ||||
| Cash Flow From Operations | 166.97 M | ||||
| Short Ratio | 4.86 X | ||||
| Earnings Per Share | 3.54 X | ||||
| Price To Earnings To Growth | 5.29 X | ||||
| Target Price | 61.0 | ||||
| Number Of Employees | 3.9 K | ||||
| Beta | 1.17 | ||||
| Market Capitalization | 1.66 B | ||||
| Total Asset | 2.31 B | ||||
| Retained Earnings | 560.28 M | ||||
| Working Capital | 361.88 M | ||||
| Current Asset | 393.34 M | ||||
| Current Liabilities | 119.72 M | ||||
| Annual Yield | 0.02 % | ||||
| Five Year Return | 0.92 % | ||||
| Net Asset | 2.31 B | ||||
| Last Dividend Paid | 0.8 |
About CONMED Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CONMED's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CONMED using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CONMED based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CONMED is a strong investment it is important to analyze CONMED's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CONMED's future performance. For an informed investment choice regarding CONMED Stock, refer to the following important reports:Check out CONMED Piotroski F Score and CONMED Altman Z Score analysis. For information on how to trade CONMED Stock refer to our How to Trade CONMED Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Medical Equipment space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CONMED. If investors know CONMED will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CONMED listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of CONMED is measured differently than its book value, which is the value of CONMED that is recorded on the company's balance sheet. Investors also form their own opinion of CONMED's value that differs from its market value or its book value, called intrinsic value, which is CONMED's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CONMED's market value can be influenced by many factors that don't directly affect CONMED's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CONMED's value and its price as these two are different measures arrived at by different means. Investors typically determine if CONMED is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CONMED's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.